Protalix BioTherapeutics, Inc. (PLX) Price Target Analysis
Analyst Rating: Buy
Based on 7 analystsNo Target Data
PLX trades at Wall Street's consensus target of —.
Current Price$2.30
Average Target—
Low—
Median—
High—
Analyst Target Range
Forward P/E11.8x
(Value)
PEG Ratio—
Implied Growth+5.6%
(Low)
Analyst Spread—
Price Forecast (1 Year)
Last 12 months price action with 12-month analyst target path
Consensus Scenario Assumptions
The base valuation assumes PLX achieves its forward estimates and maintains a stable P/E multiple of 11.8x. This scenario reflects the blended consensus of 7 Wall Street analysts, balancing both positive catalysts and macroeconomic headwinds over the next 12 months.
PLX Price Target Analysis
Updated June 28, 2026As of June 28, 2026, Protalix BioTherapeutics, Inc. (PLX) has a Wall Street consensus price target of N/A, based on estimates from 7 covering analysts. The company has a market capitalization of $185M.
Analyst price targets range from a low of N/A to a high of N/A.
The current analyst consensus rating is Buy, with 5 analysts rating the stock as a Buy or Strong Buy,2 rating it Hold, and 0 rating it Sell or Strong Sell. This overwhelmingly bullish sentiment suggests analysts see significant catalysts for upside ahead.
From a valuation perspective, PLX trades at a trailing P/E of -27.3x and forward P/E of 11.8x. Analysts expect EPS to grow +5.6% over the next year.
Our proprietary valuation model, which blends historical multiples with forward estimates, suggests a base-case price target of $1.47, with bear and bull scenarios of $0.93 and $1.94 respectively. Model confidence stands at 45/100, suggesting limited visibility into future performance.
Investment Context: Price targets represent analyst expectations for the next 12 months and should be considered alongside your own research. Targets are based on analysts' assumptions about earnings growth, margins, and market conditions which may change. For sector-specific context, view other Healthcare stocks.
Analyst Sentiment Comparison
Industry Peer AnalysisAvg Peer Upside
+23.1%
Industry Consensus
Avg Forward P/E
38.6x
(Growth Premium)
Peers with Coverage
10 / 10
Active Analyst Tracking
| Company | Market Cap | Price | Target | Upside Potential | Rating | Fwd P/E | Analysts |
|---|---|---|---|---|---|---|---|
 RAREUltragenyx Pharmaceutical Inc. | $3.0B | $30.77 | $48.36 | +57.2% | Buy | — | 33 |
 FOLDAmicus Therapeutics, Inc. | $4.5B | $14.49 | $14.50 | +0.1% | Buy | 40.6x | 24 |
 SRPTSarepta Therapeutics, Inc. | $1.8B | $16.85 | $25.14 | +49.2% | Buy | 4.8x | 54 |
 ACADACADIA Pharmaceuticals Inc. | $4.3B | $25.32 | $33.67 | +33.0% | Buy | 65.1x | 37 |
 KRYSKrystal Biotech, Inc. | $11.0B | $372.25 | $336.40 | -9.6% | Buy | 48.5x | 17 |
 PTCTPTC Therapeutics, Inc. | $7.0B | $84.43 | $95.83 | +13.5% | Buy | 95.3x | 26 |
 BMRNBioMarin Pharmaceutical Inc. | $11.3B | $59.00 | $89.21 | +51.2% | Buy | 11.9x | 41 |
 HALOHalozyme Therapeutics, Inc. | $8.9B | $74.96 | $88.25 | +17.7% | Buy | 9.2x | 27 |
 IONSIonis Pharmaceuticals, Inc. | $13.4B | $81.18 | $106.50 | +31.2% | Buy | — | 32 |
 LGNDLigand Pharmaceuticals Incorporated | $6.1B | $303.59 | $265.33 | -12.6% | Buy | 33.5x | 17 |
PLX — Frequently Asked Questions
Quick answers to the most common questions about buying PLX stock.
What is the PLX stock price target for 2026?
The consensus price target for PLX is $N/A, close to the current price of $2.3 (N/A% implied move). Based on 7 analyst estimates, the stock appears fairly valued near current levels.
Is PLX a buy, sell, or hold?
PLX has a consensus rating of "Buy" based on 7 Wall Street analysts. The rating breakdown is predominantly bullish, with 5 Buy/Strong Buy ratings. The consensus 12-month price target of $N/A implies N/A% upside from current levels.
Is PLX stock overvalued or undervalued?
With a forward P/E of 11.7949x, PLX trades at a relatively low valuation. The consensus target of $N/A implies N/A% appreciation, suggesting the market may be pricing in risks.
How high can PLX stock go?
The most bullish Wall Street analyst has a price target of $N/A for PLX, while the most conservative target is $N/A. The consensus of $N/A represents the median expectation. Our quantitative valuation model projects a bull case target of $2 based on optimistic growth and margin assumptions. These targets typically reflect 12-month expectations.
How many analysts cover PLX stock?
PLX is moderately covered, with 7 analysts providing price targets and ratings. Of these, 0 have Strong Buy ratings, 5 have Buy ratings, 2 recommend Hold, and 0 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.
What is the PLX stock forecast?
The 12-month PLX stock forecast based on 7 Wall Street analysts shows a consensus price target of $N/A, with estimates ranging from $N/A (bear case) to $N/A (bull case). The median consensus rating is "Buy". Our proprietary valuation model produces a base case fair value of $1, with bear/bull scenarios of $1/$2.
What is PLX's fair value based on fundamentals?
Our quantitative valuation model calculates PLX's fair value at $1 (base case), with a bear case of $1 and bull case of $2. The model uses discounted cash flow analysis, historical growth rates, and margin mean-reversion to project FY+2 earnings, then applies an appropriate P/E multiple. The model confidence score is 45/100.
What is PLX's forward P/E ratio?
PLX trades at a forward P/E ratio of 11.8x based on next-twelve-months earnings estimates. The higher forward P/E suggests near-term earnings pressure. A forward P/E is useful for comparing valuations when earnings are expected to change significantly.
Should I buy PLX stock?
PLX appears fairly valued according to analysts, with a "Buy" rating and minimal upside to the $N/A target. Consider your investment thesis and risk tolerance. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.
Why do PLX price targets vary so much?
PLX analyst price targets range from $N/A to $N/A, a NaN% tight range reflecting strong analyst consensus. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $N/A consensus represents the middle ground. Our model's $1-$2 range provides an independent fundamental perspective.
Consensus-Based Analysis Tools
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Check Valuation
Historical Returns
10-year return with dividends reinvested.
Calculate
DCA Calculator
See how regular investing compounds over time.
Run Numbers
Peer Comparison
Compare growth, multiples, and margins vs sector.
Compare